Translate Bio Revenue and Competitors
Estimated Revenue & Valuation
- Translate Bio's estimated annual revenue is currently $238k per year.
- Translate Bio's estimated revenue per employee is $933
Employee Data
- Translate Bio has 255 Employees.
- Translate Bio grew their employee count by 10% last year.
Translate Bio's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Head Analytical Development CMC at Translate Bio | Reveal Email/Phone |
2 | VP, Chemistry | Reveal Email/Phone |
3 | Senior Director, Legal | Reveal Email/Phone |
4 | Chief Manufacturing Officer | Reveal Email/Phone |
5 | Director and Head, DMPK/Small Molecule Bioanalytical/Proteomics | Reveal Email/Phone |
6 | Director, Chemistry at Sanofi mRNA Center Excellence | Reveal Email/Phone |
7 | Director, External Mfg | Reveal Email/Phone |
8 | Sr. Director, GMP Clinical Manufacturing | Reveal Email/Phone |
9 | Associate Director, Corporate Development | Reveal Email/Phone |
10 | Sr. Director, External Manufacturing and MS&T | Reveal Email/Phone |
Translate Bio Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $11830M | 8030 | 26% | $2.7B | $83B |
What Is Translate Bio?
Translate Bio is a leading biotechnology company focused on pioneering the translation of RNA science into therapeutics promoting healthy gene expression in people living with debilitating genetic diseases. The company's RNA platforms for powering endogenous therapeutic protein production is applicable to a broad range of diseases caused by insufficient protein production, including rare diseases of the liver, lung and central nervous system (CNS).
keywords:N/A
N/A
Total Funding
255
Number of Employees
$238k
Revenue (est)
10%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Translate Bio News
Moderna Therapeutics, CureVac, Translate Bio, BioNTech, Sangamo Therapeutics, Argos Therapeutics, In-Cell-Art, eTheRNA, Ethris, Tiba Biotechnology.
Moderna Therapeutics, CureVac, Translate Bio, BioNTech, Sangamo Therapeutics, Argos Therapeutics, In-Cell-Art, eTheRNA, Ethris,...
-- Entered into a definitive agreement under which Sanofi will acquire, subject to customary conditions to closing, all outstanding shares of Translate Bio with a goal of advancing deployment of mRNA technology across vaccines and therapeutics development -- -- Advanced mRNA infectious disease ...
Sanofi and Translate Bio initiate Phase 1/2 clinical trial of mRNA COVID-19 vaccine candidate Clinical trial to assess safety, immune response and reactogenicity, after preclinical data showed high neutralizing antibody levels Expected to enroll 415 participants; interim results expected in Q3 2 ...
LEXINGTON, Mass., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat or prevent debilitating or life-threatening diseases, today announced that Ronald R ...
Other Companies in Cambridge
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $50.5M | 255 | N/A | N/A |
#2 | $40.8M | 256 | 13% | N/A |
#3 | $94.2M | 261 | 9% | N/A |
#4 | $41.6M | 261 | 25% | N/A |
#5 | $39.3M | 261 | 7% | N/A |